In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytyc's Breakout Year

Executive Summary

Cytyc Corp., which makes the ThinPrep test for cervical cancer screening, has had a breakout year. A new deal with Quest Diagnostics Inc., reimbursement from a key managed care organization, Aetna, and weaker than expected competition is driving sales and the company's stock price.

Related Content

Cytyc Together with Hologic: There's a Certain Logic
Device M&A: The New Acquirers
Women's Health: A Growing Market for Diagnostic Players
Above and Below the Belt in Women's Health Care: Cytyc buys Proxima
Exact Sciences' Moment
Roche's End Run Into the Cervical Cancer Screening Market
Overcoming Skepticism About Cancer Diagnostics
Unsurprisingly, Cytyc Buys Digene
Dealmaking on a Small Planet: Medical Device Transactions 2001
Applying the Cytyc Formula to Breast Cancer


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts